Nothing Special   »   [go: up one dir, main page]
create a website
When is Prevention More Profitable than Cure?. (2013). Snyder, Christopher ; Kremer, Michael.
In: CID Working Papers.
RePEc:cid:wpfacu:252.

Full description at Econpapers || Download paper

Cited: 3

Citations received by this document

Cites: 62

References cited by this document

Cocites: 50

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. The Optimal Control of Infectious Diseases via Prevention and Treatment. (2020). Toxvaerd, F. M. O, ; Rowthorn, R.
    In: Cambridge Working Papers in Economics.
    RePEc:cam:camdae:2027.

    Full description at Econpapers || Download paper

  2. Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals. (2018). Snyder, Christopher ; Kremer, Michael.
    In: Review of Industrial Organization.
    RePEc:kap:revind:v:53:y:2018:i:1:d:10.1007_s11151-018-9621-4.

    Full description at Econpapers || Download paper

  3. Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals. (2018). Kremer, Michael ; Snyder, Christopher.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:12751.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Acemoglu, D. and J. Linn (2004). “Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,” Quarterly Journal of Economics 119: 1049–1090.

  2. Anderson, O. W., P. Collette, and J. J. Feldman. (1960) Expenditure Patterns for Personal Health Services, 1953 and 1958: Nationwide Survey. New York: Health Information Foundation.
    Paper not yet in RePEc: Add citation now
  3. Ault, Kevin A. (2007) “Human Papillomavirus Vaccines and the Potential for Cross-protection Between Related HPV Types,” Gynecologic Oncology 107: S31–S33.
    Paper not yet in RePEc: Add citation now
  4. Australian Government Department of Health and Ageing. (2009) Guidelines for Deeds of Agreement for Pharmaceutical Benefits Scheme (Version 1.3). Canberra, Australia.
    Paper not yet in RePEc: Add citation now
  5. Barder, O., M. Kremer, and R. Levine. (2005) Making Markets for Vaccines: Ideas to Action. Center for Global Development.
    Paper not yet in RePEc: Add citation now

  6. Blanchflower, D. G. and A. J. Oswald. (2004) “Well-Being Over Time in Britain and the USA,” Journal of Public Economics 88: 1359–1386.

  7. Boulier, B. (2006) “A Shot in the Dark: Uncertainty and Vaccine Demand and Supply,” George Washington University working paper.
    Paper not yet in RePEc: Add citation now
  8. Brito, D. L., E. Sheshinski, and M. D. Intrilligator. (1991) “Externalities and Compulsory Vaccination,” Journal of Public Economics 45: 69–90.
    Paper not yet in RePEc: Add citation now
  9. Centers for Disease Control. (2005) National Health and Examination Survey (NHANES) 2003–2004.
    Paper not yet in RePEc: Add citation now
  10. Centers for Disease Control. (2006b) HIV Prevalence Trends in Selected Populations in the United States: Results from National Serosurveillance,1993–1997. Table 3: “HIV Prevalence Among Injection Drug Users Entering Drug Treatment Centers, by Metropolitan Area and Sex, 1993–1997” downloaded April 14, 2006 from www.cdc.gov/hiv/pubs/hivprevalence/selected.htm.
    Paper not yet in RePEc: Add citation now
  11. Centers for Disease Control. (2009) “Vaccines & Preventable Diseases: List of Vaccines Used in United States,” downloaded October 10, 2009 from www.cdc.gov/vaccines/vpd-vac/vaccines-list.htm.
    Paper not yet in RePEc: Add citation now

  12. Clay, K. B., D. S. Sibley, and P. Srinagesh. (1992) “Ex Post vs. Ex Ante Pricing: Optional Calling Plans and Tapered Tariffs,” Journal of Regulatory Economics 4: 115–138.

  13. Coase, R. J. (1972) “Durability and Monopoly,” Journal of Law and Economics 15: 143–149.

  14. Corey, E. J., L. Kürti, and B. Czakó. (2007) Molecules and Medicine. Hoboken: Wiley.
    Paper not yet in RePEc: Add citation now

  15. Courty, P. (2003) “Ticket Pricing Under Demand Uncertainty,” Journal of Law and Economics 46: 627– 652.

  16. Courty, P. and H. Li. (2000) “Sequential Screening,” Review of Economic Studies 67: 697–717.
    Paper not yet in RePEc: Add citation now
  17. Dunne, E. F., et al. (2007) “Prevalence of HPV Infection Among Females in the United States,” Journal of the American Medical Association 297: 813–819.
    Paper not yet in RePEc: Add citation now
  18. Euerle, B. and P. H. Chandrasekar. (2012) “Syphilis,” in B. A. Cunha, ed., Medscape Reference. Accessed August 27, 2012 from emedicine.medscape.com/article/229461.
    Paper not yet in RePEc: Add citation now
  19. Fey Cortez, Michelle and Simeon Bennett. (2011) “Gilead HIV Breakthrough of the Year Stymied by $12,000 Cost, Side Effects,” Bloomberg News, Feb. 28. Downloaded December 29, 2012 from www.bloomberg.com/news/2011-02-28/gilead-s-12-000-a-year-hiv-prevention-pill-fails-to-win -physician-support.html Francis, P. J. (1997) “Dynamic Epidemiology and the Market for Vaccinations,” Journal of Public Economics 63: 383-406.
    Paper not yet in RePEc: Add citation now

  20. Finkelstein, A. (2004). “Static and Dynamic Effect of Health Policy: Evidence from the Vaccine Industry,” Quarterly Journal of Economics 119: 527–564.

  21. GEN News Highlights. (2012) “FDA: HIV Numbers Drove Truvada Decision,” July 17, article no. 81247053.
    Paper not yet in RePEc: Add citation now
  22. Geoffard, P.-Y. and T. Philipson. (1997) “Disease Eradication: Public vs. Private Vaccination,” American Economic Review 87: 222-230.
    Paper not yet in RePEc: Add citation now
  23. Gersovitz, M. (2003) “Births, Recoveries, Vaccinations, and Externalities,” in R. Arnott, ed., Economics for an Imperfect World: Essays in Honor of Joseph E. Stiglitz, 469–483.
    Paper not yet in RePEc: Add citation now
  24. Gersovitz, M. and J. S. Hammer. (2005) “Tax/Subsidy Policy Toward Vector-Borne Infectious Diseases,” Journal of Public Economics 89: 647–674.
    Paper not yet in RePEc: Add citation now

  25. Getzen, T. E. (2000) “Health care is an Individual Necessity and a National Luxury: Applying Multilevel Decision Models to the Analysis of Health Care Expenditures,” Journal of Health Economics 19: 259–270.

  26. Grady, D. (2012) “F.D.A. Advisory Panel Back Preventive Use of H.I.V. Drug,” New York Times, May 11: A1.
    Paper not yet in RePEc: Add citation now
  27. Greenwood, D. (2008) Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford: Oxford University Press.
    Paper not yet in RePEc: Add citation now
  28. Harpavat, S. and S. Nissim. (2001) MicroCards: Review Cards for Medical Students. Philadelphia: Lippincott Williams & Wilkins.
    Paper not yet in RePEc: Add citation now

  29. Harris, M. and A. Raviv. (1981) “A Theory of Monopoly Pricing Schemes with Demand Uncertainty,” American Economic Review 71: 347–365.

  30. Hernandez, B. Y., et al. (2008) “Transmission of Human Papillomavirus in Heterosexual Couples,” Emerging Infectious Diseases 14: 888–894.
    Paper not yet in RePEc: Add citation now
  31. Howard, Robin S. (2005) “Poliomyelitis and the Postpolio Syndrome,” British Medical Journal 330: 1314– 1318.
    Paper not yet in RePEc: Add citation now
  32. Immunization Action Coalition. (2009) Print Materials by Diseases and Vaccines downloaded October 10, 2009 from www.immunize.org/printmaterials/dis_tet.asp.
    Paper not yet in RePEc: Add citation now
  33. Kaplan, E. H. (1990) “Modeling HIV Infectivity: Must Sex Acts Be Counted?” Journal of Acquired Immune Deficiency Syndromes 3: 55–61.
    Paper not yet in RePEc: Add citation now

  34. Kessing, S. G. and R. Nuscheler. (2006) “Monopoly Pricing with Negative Network Effects: The Case of Vaccines,” European Economic Review 50: 1061–1069.

  35. Klein, B., R. A. Crawford, and A. A. Alchian. (1978) “Vertical Integration, Appropriable Rents, and the Competitive Contracting Process,” Journal of Law and Economics 21: 297–326.

  36. Kremer, M. and R. Glennerster. (2004) Strong Medicine: Creating Incentives for PharmaceuticalResearch on Neglected Diseases. Princeton: Princeton University Press.
    Paper not yet in RePEc: Add citation now
  37. Kremer, M., C. M. Snyder, and H. Williams. (2012) “Vaccines: Integrated Economic and Epidemiological Models,” mimeo, Harvard University.
    Paper not yet in RePEc: Add citation now
  38. Lau, Brandyn D., Brian L. Pinto, David R. Thiemann, and Christoph U. Lehmann. (2011) “Budget Impact Analysis of Conversion from Intravenous to Oral Medication When Clinically Eligible for Oral Intake,” Clinical Therapeutics 33: 1792–1796.
    Paper not yet in RePEc: Add citation now

  39. Lewis, T. R. and D. E. M. Sappington. (1994) “Supplying Information to Facilitate Price Discrimination,” International Economic Review 35: 309–327.

  40. Maleug, D. A. and C. M. Snyder (2006) “Bounding the Relative Profitability of Price Discrimination,” International Journal of Industrial Organization 24: 995-1011.
    Paper not yet in RePEc: Add citation now
  41. Malueg, D. A. (1994) “Monopoly Output and Welfare: The Role of Curvature of the Demand Function,” Journal of Economic Education 25: 235–250.
    Paper not yet in RePEc: Add citation now
  42. Mandell, G. L., J. E. Bennett, and R. Dolin. (2009) Principles and Practice of Infectious Diseases seventh edition. Philadelphia: Elsevier Churchill Livingstone.
    Paper not yet in RePEc: Add citation now

  43. Miravete, E. (1996) “Screening Consumers Through Alternative Pricing Mechanisms,” Journal of Regulatory Economics 9: 111–132.

  44. Morbidity and Mortality Weekly Report. (various years) “Summary of Notifiable Diseases, United States,” Centers for Disease Control and Prevention, downloaded December 20, 2009 from www.cdc.gov/-mmwr/mmwr_nd/index.html Mueller, Steffen, Eckard Wimmer, and Jeronimo Cello. (2005) “Poliovirus and Poliomyelitis: A Tale of Guts, Brains, and an Accidental Event,” Virus Research 111: 175–193.
    Paper not yet in RePEc: Add citation now
  45. National Cancer Institute. (2009) “BRCA1 and BRCA2: Cancer Risk and Genetic Testing,” National Cancer Institute Fact Sheet. Retrieved August 16, 2012, from www.cancer.gov/cancertopics/factsheet/-Risk/BRCA.
    Paper not yet in RePEc: Add citation now
  46. National Network for Immunization Information. (2009) “Vaccine Information,” downloaded October 10, 2009 from www.immunizationinfo.org/vaccineInfo/index.cfm.
    Paper not yet in RePEc: Add citation now

  47. Newell, R., A. Jaffee, and R. N. Stavins. (1999) “The Induced Innovation Hypothesis and Energy-Saving Technological Change,” Quarterly Journal of Economics 114: 907–940.

  48. Newhouse, J. P. (1977) “Medical Care Expenditure: A Cross-National Survey,” Journal of Human Resources 12: 115–125.

  49. Nowsheen, S., et al. (2012) “ER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair,” Cancer Research 72: 4796–4806.
    Paper not yet in RePEc: Add citation now

  50. Oster, E., I. Shoulson, K. Quaid, and E. R. Dorsey. (2010) “Genetic Adverse Selection: Evidence from Long-Term Care Insurance and Huntington Disease,” Journal of Public Economics 94: 1041–1050.

  51. Pecorino, P. (2002) “Should the US Allow Prescription Drug Reimports from Canada?” Journal of Health Economics 21: 699–708.

  52. Rockstroh, J. K., et al. (1995) “Male-to-Female Transmission of HIV in a Cohort of Hemophiliacs— Frequency, Risk Factors and Effect of Sexual Counseling,” Infection 23: 29–32.
    Paper not yet in RePEc: Add citation now
  53. Rosenberg, E. (1999) “Drug Makers Shy from Work on AIDS Vaccine,” San Francisco Examiner. March 16.
    Paper not yet in RePEc: Add citation now
  54. Royce, R. A., et al. (1997) “Sexual Transmission of HIV,” New England Journal of Medicine 336: 1072– 1078.
    Paper not yet in RePEc: Add citation now
  55. Snyder, C. M., W. Begor, and E. R. Berndt. (2011) “Economic Perspectives on the Advance Market Commitment for Pneumococcal Vaccines,” Health Affairs 30: 1508–1517.
    Paper not yet in RePEc: Add citation now

  56. Stole, L. A. and J. Zwiebel. (1996) “Organizational Design and Technology Choice under Intrafirm Bargaining, ” American Economic Review 86: 195–222.

  57. Thomas, P. (2002) “The Economics of Vaccines,” Harvard Medical International (HMI) World. September /October.
    Paper not yet in RePEc: Add citation now
  58. U.S. Food and Drug Administration. (2009) “Complete List of Vaccines Licensed for Immunization and Distribution in the US,” downloaded October 10, 2009 from www.fda.gov/BiologicsBloodVaccines/-Vaccines/ApprovedProducts/ucm093833.htm.
    Paper not yet in RePEc: Add citation now
  59. UNAIDS. (2000) Epidemiological Fact Sheets by Country.
    Paper not yet in RePEc: Add citation now
  60. UNAIDS. (2004) USA: Epidemiological Fact Sheets on HIV/AIDS and Sexually-Transmitted Infections.
    Paper not yet in RePEc: Add citation now
  61. Washington, D.C. Centers for Disease Control. (2006a) “Cases of HIV Infection and AIDS in the United States, 2004,” HIV/AIDS SurveillanceReport, vol. 16. Table 8: “Estimated Numbers of Persons Living with HIV/AIDS, by Year and Selected Characteristics, 2001-2004—35 Areas with Confidential Name-Based HIV Infection Reporting” downloaded March 25, 2006 from www.cdc.gov/hiv/topics/surveillance/resources/-reports/2004report/default.htm.
    Paper not yet in RePEc: Add citation now

  62. World Bank. (2000) World Development Indicators 2000. Washington, DC.

Cocites

Documents in RePEc which have cited the same bibliography

  1. Financing innovation. (2015). Kerr, William R ; Nanda, Ramana .
    In: Research Discussion Papers.
    RePEc:bof:bofrdp:urn:nbn:fi:bof-201512141480.

    Full description at Econpapers || Download paper

  2. Regulation of the Pharmaceutical-Biotechnology Industry. (2014). Keuffel, Eric ; Danzon, Patricia M..
    In: NBER Chapters.
    RePEc:nbr:nberch:12572.

    Full description at Econpapers || Download paper

  3. Demand Forces of Technical Change Evidence from the Chinese Manufacturing Industry. (2013). Zweimüller, Josef ; Zilibotti, Fabrizio ; Beerli, Andreas ; Zweimuller, Josef ; Weiss, Franziska .
    In: Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order.
    RePEc:zbw:vfsc13:79980.

    Full description at Econpapers || Download paper

  4. Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics. (2013). Edith L. Maes DBA, ; Daems, Rutger P..
    In: Working Papers.
    RePEc:msm:wpaper:2013/07.

    Full description at Econpapers || Download paper

  5. Efficient Self-Protection and Progress in Curing-Technology. (2013). Sorek, Gilad.
    In: Auburn Economics Working Paper Series.
    RePEc:abn:wpaper:auwp2013-07.

    Full description at Econpapers || Download paper

  6. Pharmaceutical patents and prices : a preliminary empirical assessment using data from India. (2012). Goyal, Aparajita ; Duggan, Mark.
    In: Policy Research Working Paper Series.
    RePEc:wbk:wbrwps:6063.

    Full description at Econpapers || Download paper

  7. Induced Innovation and Social Inequality: Evidence from Infant Medical Care. (2012). Richards-Shubik, Seth ; Cutler, David M. ; Meara, Ellen .
    In: Journal of Human Resources.
    RePEc:uwp:jhriss:v:46:y:2012:ii:1:p:456-492.

    Full description at Econpapers || Download paper

  8. The Effect of U.S. Health Insurance Expansions on Medical Innovation. (2012). Clemens, Jeffrey.
    In: Discussion Papers.
    RePEc:sip:dpaper:11-016.

    Full description at Econpapers || Download paper

  9. When More Poor Means Less Poverty: On Income Inequality and Purchasing Power. (2012). Nilsson, Therese ; Bergh, Andreas.
    In: Working Papers.
    RePEc:hhs:lunewp:2012_002.

    Full description at Econpapers || Download paper

  10. When More Poor Means Less Poverty: On Income Inequality and Purchasing Power. (2012). Nilsson, Therese ; Bergh, Andreas.
    In: Working Paper Series.
    RePEc:hhs:iuiwop:0900.

    Full description at Econpapers || Download paper

  11. Carbon Taxes, Path Dependency and Directed Technical Change: Evidence from the Auto Industry. (2012). van Reenen, John ; Martin, Ralf ; Hemous, David ; Dechezleprêtre, Antoine ; Aghion, Philippe ; Dechezlepretre, Antoine ; VanReenen, John .
    In: Working Papers.
    RePEc:fem:femwpa:2012.99.

    Full description at Econpapers || Download paper

  12. The nascent market for “green” real estate in Beijing. (2012). Zheng, Siqi ; Wu, Jing ; Kahn, Matthew ; Deng, Yongheng.
    In: European Economic Review.
    RePEc:eee:eecrev:v:56:y:2012:i:5:p:974-984.

    Full description at Econpapers || Download paper

  13. Technological Intensity of Government Demand and Innovation. (2012). Wiederhold, Simon ; Slavtchev, Viktor.
    In: ifo Working Paper Series.
    RePEc:ces:ifowps:_135.

    Full description at Econpapers || Download paper

  14. Carbon Taxes, Path Dependency and Directed Technical Change: Evidence from the Auto Industry. (2012). van Reenen, John ; Martin, Ralf ; Hemous, David ; Dechezleprêtre, Antoine ; Aghion, Philippe ; Dechezlepretre, Antoine ; VanReenen, John .
    In: CEP Discussion Papers.
    RePEc:cep:cepdps:dp1178.

    Full description at Econpapers || Download paper

  15. The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. (2011). Toole, Andrew A..
    In: ZEW Discussion Papers.
    RePEc:zbw:zewdip:11063.

    Full description at Econpapers || Download paper

  16. Market Share Exclusion. (2011). Packalen, Mikko.
    In: Working Papers.
    RePEc:wat:wpaper:1103.

    Full description at Econpapers || Download paper

  17. Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan. (2011). Chang, Chia-Lin ; Hsieh, Chee-Ruey ; Liu, Ya-Ming .
    In: MPRA Paper.
    RePEc:pra:mprapa:35147.

    Full description at Econpapers || Download paper

  18. Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry. (2011). Higgins, Matthew ; Chatterjee, Chirantan ; Branstetter, Lee G..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:17188.

    Full description at Econpapers || Download paper

  19. The Impact of Government Procurement Composition on Private R&D Activities. (2011). Wiederhold, Simon ; Slavtchev, Viktor.
    In: Jena Economic Research Papers.
    RePEc:jrp:jrpwrp:2011-036.

    Full description at Econpapers || Download paper

  20. Understanding R&D Policy: Efficiency or Politics?. (2011). Perez Sebastian, Fidel ; Perez-Sebastian, Fidel.
    In: Working Papers. Serie AD.
    RePEc:ivi:wpasad:2011-17.

    Full description at Econpapers || Download paper

  21. Opportunities and benefits as determinants of the direction of scientific research. (2011). Packalen, Mikko ; Bhattacharya, Jay.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:30:y:2011:i:4:p:603-615.

    Full description at Econpapers || Download paper

  22. Investments in Pharmaceuticals Before and After TRIPS. (2011). Kyle, Margaret ; McGahan, Anita M.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:8371.

    Full description at Econpapers || Download paper

  23. The effect of newer drugs on health spending: do they really increase the costs?. (2010). Köksal, Bülent ; Abdulkad&idot;r C&idot;van, ; Koksal, Bulent .
    In: Health Economics.
    RePEc:wly:hlthec:v:19:y:2010:i:5:p:581-595.

    Full description at Econpapers || Download paper

  24. Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes. (2010). Huang, Weng-Foung ; Chen, Pei-Fen ; Kuo, Ken ; Shih, Hsin-Wei ; Lee, Yue-Chune ; Wen, Yu-Wen ; Tsai, Yi-Wen.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:11:y:2010:i:3:p:279-290.

    Full description at Econpapers || Download paper

  25. Complements and potential competition. (2010). Packalen, Mikko.
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:28:y:2010:i:3:p:244-253.

    Full description at Econpapers || Download paper

  26. Investments in Pharmaceuticals Before and After TRIPS. (2009). Kyle, Margaret ; McGahan, Anita .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:15468.

    Full description at Econpapers || Download paper

  27. Induced Innovation and Social Inequality: Evidence from Infant Medical Care. (2009). Richards-Shubik, Seth ; Cutler, David ; Meara, Ellen .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:15316.

    Full description at Econpapers || Download paper

  28. Income and Health Spending: Evidence from Oil Price Shocks. (2009). Notowidigdo, Matthew ; Finkelstein, Amy ; Acemoglu, Daron.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:14744.

    Full description at Econpapers || Download paper

  29. Income and Health Spending: Evidence from Oil Price Shocks. (2009). Notowidigdo, Matthew ; Finkelstein, Amy ; Acemoglu, Daron.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:7255.

    Full description at Econpapers || Download paper

  30. The Value of Life in General Equilibrium. (2008). Sun, Eric ; Philipson, Tomas ; Mulligan, Casey ; Jena, Anupam.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:14157.

    Full description at Econpapers || Download paper

  31. The Other Ex-Ante Moral Hazard in Health. (2008). Packalen, Mikko ; Bhattacharya, Jay.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:13863.

    Full description at Econpapers || Download paper

  32. Is Medicine an Ivory Tower? Induced Innovation, Technological Opportunity, and For-Profit vs. Non-Profit Innovation. (2008). Packalen, Mikko ; Bhattacharya, Jay.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:13862.

    Full description at Econpapers || Download paper

  33. The Impact of Medicare Part D on Pharmaceutical R&D. (2008). Sood, Neeraj ; Blume-Kohout, Margaret.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:13857.

    Full description at Econpapers || Download paper

  34. The Supply Side of Innovation: H-1B Visa Reforms and US Ethnic Invention. (2008). Lincoln, William ; Kerr, William.
    In: Harvard Business School Working Papers.
    RePEc:hbs:wpaper:09-005.

    Full description at Econpapers || Download paper

  35. Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act. (2008). Rzakhanov, Zaur .
    In: Research Policy.
    RePEc:eee:respol:v:37:y:2008:i:4:p:673-689.

    Full description at Econpapers || Download paper

  36. Growth leaders. (2008). Etro, Federico.
    In: Journal of Macroeconomics.
    RePEc:eee:jmacro:v:30:y:2008:i:3:p:1148-1172.

    Full description at Econpapers || Download paper

  37. Market incentives and pharmaceutical innovation. (2008). Yin, Wesley.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:27:y:2008:i:4:p:1060-1077.

    Full description at Econpapers || Download paper

  38. A primer on the economics of re-importation of prescription drugs. (2007). Berndt, Ernst R..
    In: Managerial and Decision Economics.
    RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:415-435.

    Full description at Econpapers || Download paper

  39. If it aint broke, dont price fix it: the OFT and the PPRS. (2007). Towse, Adrian.
    In: Health Economics.
    RePEc:wly:hlthec:v:16:y:2007:i:7:p:653-665.

    Full description at Econpapers || Download paper

  40. The Welfare Effects of Public Drug Insurance. (2007). Sood, Neeraj ; Lakdawalla, Darius.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:13501.

    Full description at Econpapers || Download paper

  41. Is it possible to have cheaper drugs and preserve the incentive to innovate? The benefits of privatizing the drug approval process. (2007). Sauer, Robert.
    In: The Journal of Technology Transfer.
    RePEc:kap:jtecht:v:32:y:2007:i:5:p:509-524.

    Full description at Econpapers || Download paper

  42. Demographics and Industry Returns. (2007). DellaVigna, Stefano ; Della Vigna, Stefano ; Pollet, Joshua M..
    In: American Economic Review.
    RePEc:aea:aecrev:v:97:y:2007:i:5:p:1667-1702.

    Full description at Econpapers || Download paper

  43. Wants and Past Knowledge: Growth Cycles with Emerging Industries. (2006). Horii, Ryo.
    In: Development and Comp Systems.
    RePEc:wpa:wuwpdc:0504007.

    Full description at Econpapers || Download paper

  44. Wants and Past Knowledge: Growth Cycles with Emerging Industries. (2006). Horii, Ryo.
    In: Discussion Papers in Economics and Business.
    RePEc:osk:wpaper:0603.

    Full description at Econpapers || Download paper

  45. Did Medicare Induce Pharmaceutical Innovation?. (2006). Linn, Joshua ; Finkelstein, Amy ; Acemoglu, Daron ; Cutler, David.
    In: Scholarly Articles.
    RePEc:hrv:faseco:2664267.

    Full description at Econpapers || Download paper

  46. Innovation and competitive pressure. (2006). Vives, Xavier.
    In: IESE Research Papers.
    RePEc:ebg:iesewp:d-0634.

    Full description at Econpapers || Download paper

  47. Procuring Innovation. (2006). Spagnolo, Giancarlo ; Denicolo', Vincenzo ; Cozzi, Guido ; Cabral, Luis ; Zanza, Matteo.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:5774.

    Full description at Econpapers || Download paper

  48. Income Distribution and Demand-Induced Innovations. (2005). Zweimüller, Josef ; Foellmi, Reto.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:4985.

    Full description at Econpapers || Download paper

  49. Innovation and Competitive Pressure. (2005). Vives, Xavier.
    In: Department of Economics, Working Paper Series.
    RePEc:cdl:econwp:qt1s1059vr.

    Full description at Econpapers || Download paper

  50. Income Distribution and Demand-induced Innovations. (). Zweimüller, Josef ; Foellmi, Reto.
    In: IEW - Working Papers.
    RePEc:zur:iewwpx:212.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2025-01-08 23:21:24 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.